JAIC
ATRA icon

Josh Arnold Investment Consultant’s Atara Biotherapeutics ATRA Stock Holding History

Josh Arnold Investment Consultant’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,000
Closed -$300K – 26
2023
Q3 		$300K Buy
8,000
+1,200
+18% +$53.4K 0.31% 16
2023
Q2 		$274K Buy
6,800
+4,600
+209% +$260K 0.27% 18
2023
Q1 		$160K Buy
2,200
+120
+6% +$11.6K 0.19% 14
2022
Q4 		$171K Buy
2,080
+880
+73% +$91.7K 0.25% 15
2022
Q3 		$113K Hold
1,200
– – 0.15% 12
2022
Q2 		$234K Buy
+1,200
New +$196K 0.3% 14

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Josh Arnold Investment Consultant's ATRA Position: Q4 2023 in Review

Josh Arnold Investment Consultant sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 8,000 shares — an estimated $300K sold.

Josh Arnold Investment Consultant first reported a position in ATRA in Q2 2022 and held it in 6 quarters. The position peaked at $300K in Q3 2023. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Josh Arnold Investment Consultant reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Josh Arnold Investment Consultant sold 8,000 Atara Biotherapeutics shares in Q4 2023, an estimated $300K.
  • Josh Arnold Investment Consultant first reported a position in Atara Biotherapeutics in Q2 2022 and held it in 6 quarters.
  • Josh Arnold Investment Consultant's Atara Biotherapeutics position peaked at $300K in Q3 2023.
  • 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Josh Arnold Investment Consultant's 13F filing for Q4 2023, filed 7 Feb 2024.